Vaccinal preparations
AssigneeMitsubishi Chemical Corporation
InventorsHiroshi Shiku, Junzo Sunamoto, Hideo Nakamura
Life of this patent
Estimating the term…
Abstract
Vaccinal preparations comprising an antigen such as tumor-associated antigens and viral antigens, together with a hydrophobized polysaccharide as adjuvant, e.g., hydrophobized polysaccharides containing a saccharide unit whose primary hydroxyl group is represented by the following formula: —O—(CH2)mCONH(CH2)nNH—CO—O—R wherein R represents an alkyl group or a sterol residue; m represents 0 or 1; and n represents an arbitrary positive integer, at a ratio of one to five units per 100 saccharide units that constitute the polysaccharide, preferably comprising an antigen encapsulated in microparticles of aggregated hydrophobized polysaccharide.
Claims56
A parenteral vaccinal preparation comprising hydrophobized polysaccharide and antigen, wherein the hydrophobized polysaccharide comprises from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units and wherein the antigen is selected from tumor-associated antigens, viral antigens and autoantigen-reactive T-cell receptors.
A parenteral vaccinal preparation comprising hydrophobized polysaccharide and antigen, wherein the hydrophobized polysaccharide comprises hydrophobic groups in a ratio of modifications to molecule of about 5% by weight or less and wherein the antigen is selected from tumor-associated antigens, viral antigens and autoantigen-reactive T-cell receptors.
A microparticle for use in a vaccinal preparation, the microparticle consisting essentially of hydrophobized polysaccharide and antigen selected from tumor-associated antigens, viral antigens and autoantigen-reactive T-cell receptors.
A parenteral vaccinal preparation comprising an antigen and an adjuvant, wherein the adjuvant comprises a hydrophobized polysaccharide having from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units and wherein the antigen is selected from tumor-associated antigens, viral antigens and autoantigen-reactive T-cell receptors.
A method of immunization which comprises parenterally administering to a mammal a vaccinal preparation comprising hydrophobized polysaccharide and antigen.
A method of preventing a condition selected from a viral disease and an autoimmune disease, in a mammal, wherein the method comprises parenterally administering to said mammal a pharmaceutical preparation comprising hydrophobized polysaccharide and antigen.
A method of treating a condition selected from cancer, a viral disease and an autoimmune disease, in a mammal in need of such treatment, wherein the method comprises parenterally administering to said mammal an effective amount of a vaccinal preparation comprising hydrophobized polysaccharide and antigen.
A process for making a vaccinal preparation comprising a hydrophobized polysaccharide and an antigen, the process comprising mixing microparticles of aggregated hydrophobized polysaccharide and antigen and subjecting the resultant mixture to gel chromatography.
A vaccinal preparation comprising hydrophobized polysaccharide and antigen, wherein the hydrophobized polysaccharide comprises from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units and wherein the antigen is selected from tumor-associated antigens.
A process for making a pharmaceutical composition comprising at least one active ingredient, comprising combining the at least one active ingredient with an adjuvant, wherein the adjuvant comprises a hydrophobized polysaccharide having from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units.
A vaccinal preparation comprising hydrophobized polysaccharide and antigen, wherein the hydrophobized polysaccharide is selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units and wherein the antigen is erbB-2 protein.
A complex comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A microparticle for use in a vaccinal preparation, the microparticle comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A method of immunization which comprises parenterally administering to a mammal a vaccinal preparation comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A method of inducing cytotoxic T-cells which comprises administering to a mammal a vaccinal preparation comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A method of activating cytotoxic T-cells which comprises administering to a mammal a vaccinal preparation comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A method of treating cancer in a mammal in need of such treatment, wherein the method comprises parenterally administering to said mammal a therapeutically effective amount of a vaccinal preparation comprising erbB-2 protein and a hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units.
A process for making a vaccinal preparation, the process comprising mixing microparticles of erbB-2 protein and aggregated hydrophobized polysaccharide selected from (a) mannan having a molecular weight of about 55,000 and being modified with about 2.3 cholesterol residues per 100 monosaccharide units and (b) pullulan having a molecular weight of about 108,000 and being modified with about 0.9 cholesterol residues per 100 monosaccharide units, and subjecting the resultant mixture to gel chromatography.
Dependencies are inferred from the claim text.